Clinical Trials Logo

Clinical Trial Summary

Gemcitabine and nab-paclitaxel are one standard of care for metastatic pancreatic adenocarcinoma (mPDAC) but the progression free survival (PFS) of the regimen is only 5.5 months. Previous phase II study showed gemcitabine and nab-paclitaxel plus cisplatin had a PFS of 10.1 months in mPDAC. However, the nephrotoxicity of cisplatin is always a concern therefore cisplatin was substituted with oxaliplatin in current study. S-1 monotherapy has shown promising anti-tumor activity against PDAC with a manageable safety profile which provided the opportunity of combination with other agents. In this study, we will evaluate the efficacy and safety of gemcitabine, nab-paclitaxel plus S-1/LV (GASL) against gemcitabine, nab-paclitaxel plus oxaliplatin (GAP) in patients with mPDAC.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05026905
Study type Interventional
Source National Health Research Institutes, Taiwan
Contact Yung-Yeh Su, M.D.
Phone 886-6-7000123
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date October 1, 2021
Completion date December 31, 2027